scholarly journals A CASE STUDY ON SCHIZOPHRENIA INDUCED MULTIPLE COMORBIDITIES

2018 ◽  
Vol 11 (6) ◽  
pp. 1
Author(s):  
Jagadeesan M ◽  
Kiran Kumar R ◽  
Justin Jacob Abraham
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Antipsychotic Drugs ◽  
Hypoglycemic Agents ◽  
Systemic Hypertension ◽  
Inferior Wall ◽  
Cardiovascular Risks ◽  
Coronary Syndrome ◽  
Schizophrenic Patients

Schizophrenia is a mental disorder characterized by abnormal social behavior which includes false beliefs, confusion, and auditory hallucination. Antipsychotic drugs therapy increases the risk of developing diabetes mellitus and coronary artery disease (CAD) in schizophrenic patients. Hence, we have planned for a systematic approach toward the management of comorbidities induced in schizophrenic patients. A case study was conducted in 42-year-old female patient diagnosed with schizophrenia along with Type-2 diabetes mellitus, hypothyroidism, diabetic retinopathy, diabetic nephropathy, systemic hypertension, CAD-acute coronary syndrome recent inferior wall myocardial infarction. The patient was treated with atypical antipsychotics, antiplatelets, antianginals, statins, hypoglycemic agents, and other supportive measures. The patient improved symptomatically. The antipsychotic treatment for schizophrenia induces abnormal metabolic syndrome which results in decreased glucose and lipid metabolism that leads to obesity, hyperglycemia, and dyslipidemia associated with cardiovascular risks. Often antipsychotics are combined with benzodiazepines and antiparkinson agents to reduce the risks caused from large doses of antipsychotic medication. However, people receiving first-generation antipsychotics have higher prevalence of developing diabetes mellitus and cardiac risks compared to second-generation antipsychotics. Hence, we conclude that atypical antipsychotic drugs such as amisulpride, aripiprazole, and ziprasidone should be given to schizophrenic patients because these drugs have little effects on abnormal metabolic syndrome when compared to other antipsychotics. There is a need for proper screening of blood glucose level and cardiovascular risks assessment before the administration of antipsychotic medications to schizophrenic patients and also during the course of treatment regularly.

Study of co-morbidities in patients of chronic obstructive pulmonary disease at a tertiary hospital

2021 ◽  
Vol 19 (3) ◽  
pp. 122-125
Author(s):  
Rohit Chordia ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Tertiary Hospital ◽  
Systemic Hypertension ◽  
Cardiac Abnormalities ◽  
Copd Patients ◽  
Obstructive Sleep

Background: Comorbidities are important events in the natural history of the disease and have a negative effect on the morbidity and mortality of COPD patients. It is increasingly recognized that, many patients with COPD have co-morbidities that have a major impact on quality of life and survival. Present study aims at studying the prevalence and effects of comorbidities in COPD patients at a tertiary hospital. Material and Methods: Present study was cross sectional, observational study conducted in COPD patients, diagnosed for more than 5 years, underwent investigations for various comorbidities. Results: In present study, 130 COPD patients were studied for various co-morbidities. Majority of cases were from 50 -64 years age group (49.23 %) and were male (97.69 %). Smoking was major factor noted among cases (73.85 %), out of them 23.96 % were current smoker. Mean duration since quitting of smoking was 7.24 ± 5.83 years. Comorbidities noted in present study were systemic hypertension (42.31 %), GERD and gastric ulceration (31.54 %), type 2 diabetes mellitus (30.77 %), metabolic syndrome (29.23 %), anemia (11.54 %), left sided cardiac abnormalities (10.77 %), depression (8.46 %), obstructive sleep apnea (6.92 %), ischemic heart disease (6.15 %), osteoporosis (4.62 %), bronchiectasis (2.31 %) and lung cancer (0.77 %). Conclusion: Comorbidities noted in present study were hypertension, GERD, type 2 diabetes mellitus, metabolic syndrome, anaemia, left sided cardiac abnormalities and depression.

P105: Frailty as a consequence of the metabolic syndrome (case study of the diabetes mellitus type 2)

2014 ◽  
Vol 5 ◽  
pp. S116
Author(s):  
M. Pozdnyakova ◽  
K.I. Prashchayeu ◽  
N. Ilnitski ◽  
V. Pavlova ◽  
V. Bashuk ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
The Metabolic Syndrome

Outcome of Patients Hospitalized with Acute Coronary Syndrome Fulfilling the Criteria of Metabolic Syndrome

2014 ◽  
Vol 15 (1) ◽  
pp. 31-35
Author(s):  
Mohammed Shahadat Hossain ◽  
Khan Abul Kalam Azad ◽  
Prodip Kumar Biswas ◽  
Md. Amir Hossain ◽  
Jayanta Kumar Saha ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Acute Coronary Syndrome ◽  
Heart Block ◽  
Cardiovascular Complications ◽  
Coronary Syndrome ◽  
Group I ◽  
Significant Difference ◽  
Group Ii ◽  
The Impact

The aim of the study was to assess the association of metabolic syndrome in patients with acute coronary syndrome and the impact of metabolic syndrome on clinical outcome. Total 210 ACS patients were included in this study and divided in group I & II on the basis of presence or absence of MS respectively. Among the study patients mean age in group I and group II was 52.99 ± 11.49 years and 53.34 ± 12.54 years respectively. Among the risk factors, hypertension (70%vs 15%), dyslipidemia (100 vs. 97%), diabetes mellitus (36.4% vs. 6%) were significant between two groups. Mean waist circumference recorded was 103.12 ± 4.15 in group I and 96.50 ± 6.43 in group II which was significant. Present study showed, in hospital outcome was worse in group I in comparison to group II and was significant, like cardiogenic shock (11% vs. 1%), LVF (28.2% vs. 16%), and CVD (5.45 vs. 0%). But there were no significant difference in heart block, tachyarrhythmia, cardiac arrest, reinfarction and death. Complications were far more in group I than in group II (14.5% vs. 52.0%) which was also highly significant. So, we conclude that the presence of MS in patients suffered from ACS was associated with a greater incidence of in-hospital cardiovascular complications and mortality.DOI: http://dx.doi.org/10.3329/jom.v15i1.19857 J Medicine 2014; 15: 31-35

scholarly journals Diabetes mellitus and chronic coronary syndrome

2021 ◽  
Vol 17 (1) ◽  
pp. 43-55
Author(s):  
V.A. Serhiyenko ◽  
A.A. Serhiyenko
Keyword(s):  
Diabetes Mellitus ◽  
Cardiovascular Diseases ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Stress Tests ◽  
Cardiovascular Risks ◽  
Bicycle Ergometry ◽  
Converting Enzyme Inhibitors ◽  
Coronary Syndrome

Chronic coronary syndrome is characterized by the development of episodes of ischemia due to an imbalance between needs and blood supply to the myocardium. Such episodes are usual­ly provoked by physical or emotional stress or other stressful situations, but can also occur spontaneously. Angina attacks are a classic manifestation of myocardial ischemia. In some cases, the disease may be asymptomatic for a while and begin immediately with acute coronary syndrome. Chronic coronary syndrome may have a long preclinical period on the background of confirmed coronary athe­rosclerosis. This review analyses the relevant data about the current state of the problem of diabetes mellitus and chronic coronary syndrome. In particular, the issues related to the peculiarities of risk assessment, the main factors causing a very high risk of atherosclerotic cardiovascular diseases; classification, the main characteristics of chronic coronary syndrome and its features in diabetes mellitus; diagnosis of chronic coronary syndrome (dosed physical acti­vity — bicycle ergometry, treadmill test, or stress tests; single-photon emission computed tomography, stress echocardiography; stress cardiac magnetic resonance imaging, positron emission tomography ­using radioactive tracers) were considered. Features of conservative therapy for chronic coronary syndrome against the background of diabetes mellitus (prescription of antiplatelet agents, β-adrenergic receptor blockers, calcium channel blockers, nitrates, angiotensin-converting enzyme inhibitors, myocardial cytoprotectors, statins) were analyzed. Treatment of a patient with a combination of diabetes mellitus and chronic coronary syndrome will be successful only if adequate antidiabetic therapy that is safe in terms of hypoglycemia and possible cardiovascular risks, on the one hand, and metabolically neutral antianginal therapy, on the other, is prescribed. Undoubtedly, it is necessary to pay attention to the correction of risk factors for cardiovascular diseases, hypertension and chronic heart failure.

scholarly journals The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

2012 ◽  
Vol 58 (5) ◽  
pp. 75-79
Author(s):  
T V Saprina ◽  
T K Gudkova ◽  
V A Stoliarova ◽  
S Iu Martynova ◽  
N G Dudar'kova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Risk Factor ◽  
Combined Therapy ◽  
The Body ◽  
Hypoglycemic Agents ◽  
Cardiovascular Risks

The optimal control of diabetes mellitus (DM) should ensure not only the achievement and maintenance of the targeted blood glucose level but also the reduction of other cardiovascular risks. Obesity is a key risk factor of the development of type 2 diabetes mellitus (DM2) and an independent risk factor of cardiovascular complications. The agonists of glucagon-like peptide-1 (GLP-1) are currently considered to be the sole hypoglycemic agents that not only effectively correct hyperglycemia but also reduce the excessive body weight. Liraglutide (Victoza, Novo Nordisk) is the first long-acting analog of human GLP-1 approved for the application in the treatment of DM2 at the early stages of the disease in the form of both mono- and combined therapy. We present the literature review of the results of randomized clinical studies and our own experience with the use of Victoza for glycemic control and correction of the body weight in the patients presenting with type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document